Clarivate Epidemiology’s coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…
Clarivate Epidemiology's coverage of multiple sclerosis (MS) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed…
Clarivate Epidemiology's coverage of scleroderma (systemic sclerosis) comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets…
Clarivate Epidemiology's coverage of scleroderma (systemic sclerosis) comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets…
With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues…
A handful of newer disease-modifying therapies (DMTs) for multiple sclerosis (MS)—Novartis’s Mayzent, Bristol Myers Squibb’s Zeposia, Novartis’s Kesimpta, and Janssen’s Ponvory—have…
Scleroderma, also known as systemic sclerosis (SSc), is characterized by progressive vasculopathy, progressive fibrosis, and autoimmunity. While disease severity and symptoms are heterogeneous, in…
An increasing number of clinically unique immunomodulatory disease-modifying therapies (DMTs) are approved for the treatment of relapsing forms of multiple sclerosis (MS), the most prevalent form…
Spasticity is characterized by an increase in muscle tone and is highly prevalent among patients diagnosed with some neurological conditions (e.g., stroke, multiple sclerosis [MS], spinal cord…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment…
Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence there. Traditionally, patients suffering…
Systemic sclerosis (SSc) is a rare, progressive, debilitating autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that manifests as Raynaud’s disease, skin…